Convening on a National Strategy for Alpha-gal Syndrome
FARE is convening diverse stakeholders to align priorities, accelerate progress, and drive meaningful impact for alpha-gal syndrome patients.
Building a National Framework for Understanding Alpha-gal Syndrome (AGS)
As the prevalence of alpha-gal syndrome (AGS) continues to rise across the United States, there is an urgent need for coordinated national leadership to address the growing impact on patients, families, healthcare providers, and at-risk communities.
FARE’s multi-year collaborative initiative will bring together experts from across disciplines to identify research priorities, improve education and outreach, foster strategic partnerships, and develop a long-term roadmap to accelerate progress in diagnosis, treatment, and patient support.
Leading as a National Convener on Alpha-gal Syndrome
Why National Coordination Matters
Alpha-gal syndrome is a complex, emerging condition that sits at the intersection of allergy, infectious disease, environmental exposure, and public health. Its rapid rise across the United States—combined with gaps in awareness, diagnosis, and care—demands more than isolated efforts. It requires national coordination.
As a trusted leader in food allergy research and advocacy, FARE (Food Allergy Research & Education) is uniquely positioned to serve as a national convener—bringing together diverse stakeholders to align priorities, accelerate progress, and drive meaningful impact for patients.
AGS presents a new frontier—one that requires expanding beyond traditional allergy frameworks to include:
- Entomology and vector-borne disease experts
- Ecologists and environmental scientists
- Agricultural stakeholders and veterinarians
- Public health officials and federal agencies
- Industry partners and diagnostic innovators
FARE’s is uniquely suited to bring these disciplines together.
Building Future Solutions for Alpha-gal Syndrome—Together
The challenges of alpha-gal syndrome are too complex for any one sector to solve alone. Through proven leadership, deep expertise, and a commitment to collaboration, FARE is helping to shape a more coordinated, strategic, and effective national response to improve patient outcomes.
We are committed to ensuring that the patient voice is meaningfully reflected in this work. FARE is actively engaging with leading alpha-gal patient advocacy organizations and community leaders to inform our approach, share perspectives, and strengthen alignment across the field. This ongoing collaboration helps ensure that the lived experiences of individuals and families affected by AGS are thoughtfully incorporated as we shape research priorities, education efforts, and broader strategies to improve outcomes.
Together, we can move faster—and further—toward better outcomes for everyone affected by alpha-gal syndrome.
Initiative Goals
